Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

EAA antagonists reported by Pharmacia & Upjohn

May 26, 1997

FUB-181: Potent and selective H3 antagonist

May 23, 1997

OPC-14117 effective in mouse model of motor neuron disease

May 23, 1997

Cortex to evaluate CX-516 for the treatment of schizophrenia

May 23, 1997

Results from a comparative study of olanzapine and risperidone reported

May 22, 1997

First launch for Quadramet

May 22, 1997

NMDA antagonist/opiate combination provides superior analgesia to morphine alone

May 22, 1997

Pfizer reports prodrugs of NMDA antagonist

May 22, 1997

Glaxo Wellcome describes optically active pyrimidine useful as analgesic and anticonvulsant

May 22, 1997

Atypical neuroleptics from Merck KGaA

May 22, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...